U.S. Hospitality Stock News

When you buy and hold a stock for the long term, you definitely want it to provide a positive return. Better yet, you'd...

Those holding AeroVironment, Inc. ( NASDAQ:AVAV ) shares would be relieved that the share price has rebounded 49% in...

ITT's (NYSE:ITT) stock is up by 6.5% over the past three months. Since the market usually pay for a company’s long-term...

If you are looking at Xeris Biopharma Holdings and wondering whether the recent excitement still offers fair value, this article will walk you through what the current price might be implying. The stock last closed at US$7.93, with returns of 7.9% over the past week, 14.3% over the past month, 7.9% year to date, and 133.2% over the last year, along with a very large 3 year return that is more than 5x. Recent company news has put a spotlight on Xeris Biopharma Holdings, adding context to...

With a median price-to-sales (or "P/S") ratio of close to 0.5x in the Specialty Retail industry in the United States...

Steel Partners Holdings (SPLP) is on investors’ radar after recent share price moves, with the stock showing double digit returns over the month and the past 3 months, prompting fresh interest in its diversified operations. See our latest analysis for Steel Partners Holdings. That recent momentum sits on top of a solid year, with a 13.83% year to date share price return and a 1 year total shareholder return of 17.94%. The 5 year total shareholder return is a little under 3x. If SPLP’s move...

If you are wondering whether MACOM Technology Solutions Holdings at around US$174.87 is still a good deal or already pricing in a lot of optimism, you are not alone. The stock has been relatively flat year to date with a 0.1% decline. Yet it is up 31.6% over 1 year and 172.5% over 3 years, which hints that the market’s view on its future potential and risk has shifted over time. Recent attention on MACOM has centered around its role in semiconductors for high performance applications and how...

EyePoint Pharmaceuticals recently provided a corporate update outlining progress for its lead retinal therapy DURAVYU, including ongoing Phase 3 trials in wet age-related macular degeneration and preparations for a Phase 3 start in diabetic macular edema, as well as work toward a potential future regulatory filing in the US. This update underscored how DURAVYU sits at the center of EyePoint’s efforts to transition from minimal post-exit revenues to a focused retinal disease platform with a...

We wouldn't blame Gulfport Energy Corporation ( NYSE:GPOR ) shareholders if they were a little worried about the fact...

Looking at Silence Therapeutics plc's ( NASDAQ:SLN ) insider transactions over the last year, we can see that insiders...

Hurco Companies (HURC) closed FY 2025 with fourth quarter revenue of US$45.5 million and a basic EPS loss of US$0.48, while trailing twelve month revenue stood at US$178.6 million against a basic EPS loss of US$2.34. Over recent periods, the company has seen quarterly revenue move between US$40.9 million and US$53.7 million, with basic EPS losses ranging from US$0.22 to US$1.47. This sets a clear backdrop of pressure on profitability that keeps margins front and center for investors assessing...

LENZ Therapeutics (LENZ) shares are in focus after the company signed an exclusive distribution agreement with Lunatus Marketing & Consulting FZCO to register and commercialize its VIZZ eye drop for presbyopia across multiple Middle Eastern markets. See our latest analysis for LENZ Therapeutics. The distribution deal comes after a weak run for the stock, with a 30 day share price return of 40.62% and a 90 day share price return of 61.67%, while the 1 year total shareholder return sits at...

If you are wondering whether JBT Marel at US$156.04 is still a sensible entry point or more of a hold, the next sections will walk through what the current price may be implying about value. The stock has recorded returns of 3.6% over the past week, 1.5% over the last month, 3.6% year to date and 28.5% over the past year, with a 55.0% return over three years and 25.8% over five years. These figures can affect how investors think about both upside potential and downside risk. Recent attention...

Interface (NASDAQ:TILE) has had a great run on the share market with its stock up by a significant 15% over the last...

CVD Equipment Corporation ( NASDAQ:CVV ) shareholders have had their patience rewarded with a 36% share price jump in...

Angi Inc.'s ( NASDAQ:ANGI ) price-to-earnings (or "P/E") ratio of 17.2x might make it look like a buy right now...

Despite an already strong run, Astronics Corporation ( NASDAQ:ATRO ) shares have been powering on, with a gain of 28...

Let's talk about the popular Charles River Laboratories International, Inc. ( NYSE:CRL ). The company's shares saw a...

While Townsquare Media, Inc. ( NYSE:TSQ ) might not have the largest market cap around , it received a lot of attention...

Diversification is a key tool for dealing with stock price volatility. But the goal is to pick stocks that do better...

Lam Research Corporation ( NASDAQ:LRCX ) shares have continued their recent momentum with a 30% gain in the last month...

Insiders were net sellers of Optimum Communications, Inc.'s ( NYSE:OPTU ) stock during the past year. That is, insiders...

Alamo Group Inc.'s ( NYSE:ALG ) dividend will be increasing from last year's payment of the same period to $0.34 on...

If you are wondering whether N-able's share price around US$7.31 actually reflects its underlying worth, you are not alone. This article is built to help you size that up clearly. Over the past week the stock is roughly flat at a 0.1% return, but that sits against a 4.2% decline over 30 days and a 19.7% decline over the past year, which can change how investors view both its potential and its risks. Recent coverage has focused on how N-able is positioned within the broader software and IT...